Aralez Pharmaceuticals Inc.’s new CEO Adrian Adams offered a glimpse at his plans for the new pharmaceutical company Aralez Pharmaceuticals, which will be formed later this year out of the merger between Pozen and Tribute Pharmaceuticals Canada Inc., including “aggressively” going after deals.
Pozen’s second quarter sales and earnings call Aug. 10 was the first public forum Adams has used to outline the strategy behind the planned merger, announced June 8 [See Deal]. Previously the CEO of Auxilium Pharmaceuticals Inc